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MAGE gene family encodes peptides recognized by autologous
cytotoxic T lymphocytes in a MHC class-I restricted fashion (van
der Bruggen et al, 1991; Marchand et al, 1993; Gaugler et al,
1994) and can elicit tumour cytolytic activity in patients with
advanced melanoma (Valomori et al, 1997). De Plaen et al
documented that the MAGE gene family, MAGE-A, consists of
12 genes which locate in the chromosome Xq terminal region
(De Plaen et al, 1994). Recent investigations have identified new
MAGE genes, MAGE-B and MAGE-C1, which appear to be
located on chromosome Xp21 and Xq26 (Lurquin et al, 1997;
Lucas et al, 1998). MAGE-1 and -3 belong to MAGE-A gene
family, and are expressed in a significant proportion of tumours of
various histological malignancies, and are silent in normal somatic
cells except male germline cells (Weynants et al, 1994; Eura et al,
1995a, 1995b; Inoue et al, 1995; Patard et al, 1995; Russo et al,
1995; Shichijo et al, 1995; Toh et al, 1995; Yamada et al, 1995;
Corrias et al, 1996; Mori et al, 1996; Muramoto, 1997; Sudo et al,
1997). Among the MAGE-A gene family, by contrast, MAGE-11
is highly conserved in mammalian cells of different species,
suggesting an important function (Jurk et al, 1998). However,
the functions of the MAGE gene family have not been clarified
to date.
Analysis of MAGE-1 and -3 gene products have shown that the
molecular weight of the former is 46-kDa while that of the latter is
48-kDa (Chen et al, 1994; Schultz-Thater et al, 1994; Kocker et al,
1995; Carrel et al, 1996; Gudat et al, 1996; Gunther et al, 1997).
Immunohistochemical studies in malignant melanomas have
demonstrated that MAGE-1 gene product is a cytoplasmic protein
clustered in paranuclear organelle-like structures (Schultz-Thater
et al, 1994). MAGE-3 protein also exists in cytoplasm showing
homogeneous, focal or scattered pattern of expression, and the
expression undergoes a substantial change in distribution with
increase in tumour size and invasiveness (Gunther et al, 1997).
Hepatocellular carcinoma (HCC) is one of the most prevalent
malignancies in East Asia, including Japan (Okuda, 1992).
Problems to be resolved clinically are how to discriminate well-
differentiated HCCs from non-cancerous lesions, and how to
suppress the recurrences that frequently occur after treatment. In
the present study, we have carried out the reverse transcription
polymerase chain reaction (RT-PCR), the immunohistochemical
and the Western blot analysis for MAGE-1 and -3 genes and gene
products to determine whether detection of the genes, and whether
the proteins is available for differential diagnosis of HCC, and
whether the peptides derived from MAGE-1 and -3 proteins are
suitable targets for the immunotherapy of human HCCs.
SUBJECTS AND METHODS
We examined 33 surgically resected HCCs. The specimens were
cut into slices, formalin-fixed, paraffin-embedded and used for
immunohistochemical analysis and for routine staining with
haematoxylin and eosin. The samples were also immediately
frozen after resection, and stored at –80°C until RNA and protein
extraction. The erythroleukemia cell line K562 was used as a
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positive control of MAGE-1 and -3 gene expression (Serrano et al,
1995), while human testicular tissues were also used as a positive
control for the immunostaining and the Western blot analysis
(Carrel et al, 1996).
A profile of the 33 patients enrolled in the present study is
shown in Table 1. The subjects were 25 males and eight females
42–75 years of age, and five cases were positive for HBs antigen,
27 were positive for hepatitis C virus (HCV) antibody and one was
negative for both viral markers. Tumour-bearing non-cancerous
tissues were chronic hepatitis in 16 patients and liver cirrhosis
in 17 patients. As for tumour size, five were less than 20 mm,
26 were 20–50 mm and one was greater than 51 mm in diameter.
The histological grade and clinical stage of HCC were classified
according to the criteria outlined by the Liver Cancer Group of
Japan (1989). Well, moderately and poorly differentiated HCC
comprised 12, 19 and two cases respectively, and stage I, II, III,
IVA and IVB accounted for 9, 11, 8, 3 and 2 respectively. The
positive rate of alpha-fetoprotein higher than 200 ng/ml was 33%.
The study was approved by the institutional review board, and
informed consent for the experimental use of specimens was
obtained from all patients.
For the detection of MAGE genes, total RNA was extracted
using RNAzolB reagent (Tel-Test Inc, Texas, USA) and 2 mg of
RNA were used to synthesize cDNA by RAV-2 reverse transcrip-
tase (Takara Biomedics, Osaka, Japan). The sequences of primers
for PCR amplification were as follows: MAGE-1; sense,
5¢-CGGCCGAAGGAACCTGACCCAG-3¢ (CHO-14) and anti-
sense, 5¢-GCTGGAACCCTCACTGGGTTGCC-3¢ (CHO-12),
MAGE-3; sense, 5¢-TGGAGGACCAGAGGCCCCC-3¢ (AB-
1197), antisense, 5¢-GGACGATTATCAGGAGGCCTGC-3¢
(BLE-5). We also performed RT-PCR for MAGE-4, -6 and -12 to
confirm whether the monoclonal antibody against MAGE-3
protein used in the present study detected only MAGE-3 protein
since this monoclonal antibody has recently been found to
efficiently stain COS cells transfected with MAGE-4, -6 or
-12 genes (T Boon, personal communication). The sequences of
primers for PCR amplification were as follows: MAGE-4; sense,
5¢-ACCAAGGAGAAGATCTGCCAGTGGGTCTC-3¢ (MSFf-1)
and antisense, 5¢-GTCGCCCTCCATTGCATTGTGC-3¢ (M41 Sr),
MAGE-6; sense, 5¢- TGGAGGACCAGAGGCCCCC-3¢ (AB-
1197), antisense, 5¢-CAGGATGATTATCAGGAAGCCTGT-3¢
(MAGE-6A). MAGE-12; sense, 5¢-AGGTCAGAGAACAGC-
GAGAT-3¢ (MAGE-12S), antisense, 5¢-TTCCTGTTCT-
TCGTTGCTGG-3¢ (MAGE-12A) (Lee et al, 1996). The PCR
reaction was carried out for 35 cycles: 1 min at 94°C and 4 min at
72°C followed by a final extension for 15 min at 72°C for MAGE-
1, -3 and -6, and 1 min at 94°C and 1 min at 60°C and 3 min at
72°C followed by a final extension for 15 min for MAGE-4
Table 1. Clinical and pathological features of the subjects
Bearing Virus Tumor Histological Clinical Serum AFP
Case Sex Age(yr) liver type size(mm) grade stage level(ng/ml)
1 M 66 CH C 18 well I 4
2 F 66 LC C 18 mod I 4818
3 M 70 CH C 18 mod I 3
4 F 62 LC C 20 well I 15
5 M 71 CH C 20 well I 5
6 M 64 CH C 20 well I 17
7 M 65 LC C 20 well I n.d.
8 M 68 LC NBNC 20 mod I 14
9 M 57 CH C 27 well I 9
10 M 61 CH C 20 mod II 309
11 F 57 LC C 21 mod II 70
12 M 60 LC C 25 well II 893
13 F 46 LC B 25 mod II 5970
14 M 68 CH C 30 well II n.d.
15 M 71 LC B 30 mod II 1443
16 M 71 CH C 30 mod II n.d.
17 M 69 CH C 30 mod II 5
18 M 73 LC C 30 por II 0
19 M 64 CH C 35 well II 3
20 M 65 LC C 45 mod II 443
21 F 73 LC C 20 well III 708
22 M 56 CH B 20 well III 10
23 F 68 LC C 20 mod III 1579
24 M 67 CH C 22 mod III 11
25 M 65 LC C 30 mod III 52
26 F 75 CH C 35 mod III 104
27 M 42 CH B 40 mod III 790
28 M 67 CH C 40 mod III 251
29 M 53 LC C 20 well IVA 8
30 M 66 LC C 25 mod IVA 11
31 M 55 CH B 100 por IVA 40000
32 F 68 LC C 12 mod IVB 65
33 M 65 LC C 17 mod IVB 74
CH, chronic hepatitis; LC, liver cirrhosis; B, hepatitis B virus; C, hepatitis C virus; NBNC, non hepatitis B virus and non hepatitis C virus; AFP, alfa-feto protein;
well, well differentiated hepatocellular carcinoma; mod, moderately differentiated hepatocellular carcinoma; por, poorly differentiated hepatocellular carcinoma;
n.d., not done.1082 K Kariyama et al
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and -12. The PCR products were electrophoresed on 1% agarose
gel and visualized with ethidium bromide staining.
The Western blot analysis was performed in 15 samples. Frozen
HCC tissues were homogenized and insoluble cell debris was
removed by centrifugation at 12 000 g for 30 min. Fifty micro-
grams protein were separated by 12.5% sodium dodecyl sulphate
polyacrylamide gel electrophoresis under reducing conditions. The
separated proteins were transferred to a nitrocellulose membrane
and the membrane was blocked with 5% non-fat dry milk in phos-
phate-buffered saline (PBS) containing 0.1% Tween-20.
Monoclonal antibodies against MAGE-1 (mAb 77B) or MAGE-3
(mAb 57B) were used in the present investigation.
To generate these monoclonal antibodies BALB/c mice were
immunized with 20 mg of the respective recombinant protein.
Hybridoma supernatants were screened by ELISA for binding to
the each protein used for immunization (Kocher et al, 1995; Carrel
et al, 1996). After overnight incubation with the respective
undiluted mAb at 4°C, the membrane was washed with
PBS/Tween-20, incubated with horseradish peroxidase (HRP)-
conjugated goat anti-mouse second-step antibody (ECL Detec-
tion System, Amersham Japan, Tokyo, Japan) for 1 h.
Chemiluminescence detection system was used to reveal specific
binding (ECL Detection System, Amersham Japan, Tokyo, Japan),
and protein bands were visualized on autoradiogrphy film. A
commercially available marker of molecular weight (Sigma
Chemical Company, Tokyo, Japan) was used.
The immunohistochemical analysis of MAGE-1 and -3 was
carried out using the monoclonal antibodies mentioned above.
Briefly, 4-mm-sliced sections were deparaffinized and heated in
PBS for 10 min at 90°C. After blocking of the endogenous peroxi-
dase activity and non-specific reactivity, the first reaction with the
respective monoclonal antibodies was carried out for 1 h at room
temperature. Biotin-conjugated anti-mouse immunoglobulin was
used as the second antibody after which sections were treated with
peroxidase–streptoavidin complex (Nichirei Co Ltd, Tokyo,
Japan). The reactive products were visualized by staining with
30% 3,3¢-diaminobenzidine tetrahydrochloride (Nichirei Co Ltd,
Tokyo, Japan).
RESULTS
RT-PCR analysis for the MAGE-1 and -3 mRNAs
The expression of MAGE-1 and -3 genes in case 22 and the K562
cell were shown in Figure 1. The expected products of 421 bp and
725 bp which corresponded to MAGE-1 and -3 gene respectively,
were detected in HCC and K562 cells, but not in the non-
cancerous tissue (Figure 1).
Western blot analysis of the MAGE-1 and -3 gene
products
The Western blot analysis for MAGE-1 and -3 gene products was
performed in 15 HCC and two human testicular tissues. The mole-
cular weight of MAGE-1 and -3 protein was 46-kDa and 48-kDa
respectively, and both were clearly distinguishable. The respective
gene products were positive exclusively in HCC and testicular
tissues, and negative in the corresponding non-cancerous portions.
A 72-kDa band, which was reported to be cross-reacted with
anti MAGE-1 mAbs (Gudat et al, 1996), was detected in two of
15 HCCs. A 31-kDa band was also observed in immunoblot
analysis with mAb 57B. However, this band was only detected in
testicular tissues (Figure 2).
Immunohistochemical studies of the MAGE-1 and -3
gene products
On immunohistochemistry, MAGE-1 protein was recognized in
the cytoplasm of six HCC tissues: one showed homogenous and
five a focal distribution, of which two exhibited nuclear staining.







Figure 1 RT-PCR for MAGE-1 and -3 mRNAs. Total RNA was obtained
from a sample of hepatocellular carcinoma (HCC), the corresponding non-
cancerous tissue (liver cirrhosis, LC), and K567 cell line. The expected
products of 421 and 725 bp which corresponded to MAGE-1 and -3 gene,







Figure 2 Expression of MAGE-1 and -3 gene products by western blot
analysis using mAbs, 77B for MAGE-1 and 57B for MAGE-3. The molecular
weight of MAGE-1 was 46-kDa and that of MAGE-3 protein was 48-kDa,
respectively. These proteins were exclusively observed in HCC and the
testicular tissue. A 72-kDa band which cross-reacted with the mAb 77B was
also detected in two of 15 HCCs. A 31-kDa band was also detected with the
mAb 57B only in the testicular tissue.MAGE-1 and -3 expression in human HCC 1083
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tissues. The staining pattern was homogenous or scattered in HCC
nodules, and one was positive in the nucleus (Figures 3 and 4).
mRNA and protein expression of MAGE-1 and -3 and
clinicopathological features
The expression of MAGE-1 and -3 gene and gene product in all
cases examined was shown in Table 2. The positive rates in the
expression of MAGE-1 and -3 gene were 21/27 (77.8%) and 11/26
(42.3%) respectively. Furthermore, their gene products examined
by Western blot were positive in 12/15 (80.0%) and 9/15 (60.0%)
respectively. However, in the immunohistochemical analysis
MAGE-1 and -3 protein was detected only in 6/33 (18.2%) and
2/29 (6.9%) respectively, suggesting that the immunohistochem-
ical analysis was less sensitive than the Western blotting. All of the
samples positive in the immunohistochemical examination were
positive in the corresponding gene detection analysis, although
MAGE-1 and -3 genes were not detected in three samples positive
in the Western blot analysis (Table 2). The expression of MAGE-1
and -3 genes and proteins correlated with neither the histological
grading nor the clinical staging of HCC (Table 3).
Expression of MAGE-3, -4, -6 and -12 genes
Since there was a possibility that mAb 57B detected MAGE-4, -6
or -12 except for MAGE-3 protein, we analysed the correspon-
dence between the respective gene and the protein expression.
MAGE-4, -6 and -12 mRNA were expressed in 2/9 (22%),
7/9 (78%) and 0/9 (0%). The correspondent rates were 11/14
(79%), 2/9 (22%), 5/9 (56%) and 3/9 (33%) in MAGE-3, -4, -6 and
-12 respectively, suggesting that mAb 57B reacted mainly with
MAGE-3 gene product rather than the other proteins (Table 4).
DISCUSSION
Several tumour-associated antigens, including MAGE, BAGE,
GAGE families, Melan-A/MART-1, tyrosinase, gp100, have been
identified using cytotoxic T-cell clones and T-cell lines isolated
from melanoma patients (Bakker et al, 1995; Spagnoli et al, 1995;
Marincola et al, 1996). Among these tumour-associated antigens,
MAGE-1 and -3 are two clinically relevant and their genes are
expressed in a considerable proportion of melanomas and other





Figure 3 Immunohistochemical analysis of MAGE-1 and -3 gene products. H-E staining(a)(c). MAGE-1(b) and -3(d) gene products were detected exclusively
in the HCC portions. (´40)1084 K Kariyama et al
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gene in human HCCs agrees with that previously reported by
Yamashita et al (1996). For the induction of MAGE-1 and -3
antigen-specific tumour immunity in HCC patients, the peptide
epitopes derived from these antigens should be expressed on the
corresponding HLA class I molecules (Celis et al, 1994; van der
Bruggen et al, 1994; Yamasaki et al, 1995). Therefore, this study
was designed to investigate whether MAGE-1 and -3 proteins are
expressed in HCCs, and to determine whether the detection of the
genes and proteins is a useful tool for differential diagnosis of
HCCs from non-cancerous lesions.
Our findings first provide new information with respect to the
expression of MAGE-1 and -3 gene products in human HCCs.
Table 2. Expression of MAGE gene and gene products in all cases
Case MAGE-1 MAGE-3
No. mRNA staining immunoblot mRNA staining immunoblot
1 (–) (–) (+) (–) n.d. (+)
2 (+) (–) n.d. (–) (–) n.d.
3 (–) (–) n.d. (–) n.d. n.d.
4 (+) (–) n.d. (–) (–) n.d.
5 (+) (–) n.d. (+) (–) n.d.
6 n.d. (–) n.d. n.d. (–) n.d.
7 (+) (–) (–) (–) (–) (–)
8 (+) (–) (+)* (–) (–) (+)
9 (+) (–) n.d. n.d. (–) n.d.
10 (+) (+) (+) (–) (–) (–)
11 (+) (+) n.d. (+) (–) n.d.
12 (–) (–) n.d. (–) (–) n.d.
13 (+) (–) (+) (–) (–) (–)
14 n.d. (–) (+)* n.d. (–) (+)
15 (+) (–) n.d. (+) (–) n.d.
16 (+) (–) (–) (–) n.d. (–)
17 n.d. (–) n.d. n.d. (–) n.d.
18 (+) (+) (+) (+) (–) (+)
19 n.d. (–) n.d. n.d. (–) n.d.
20 (+) (–) n.d. (+) (–) n.d.
21 n.d. (–) n.d. n.d. (–) n.d.
22 (+) (+) (+) (+) (+) (+)
23 n.d. (–) n.d. n.d. n.d. n.d.
24 (–) (–) (+) (+) (–) (+)
25 (+) (+) (+) (+) (+) (+)
26 (+) (–) (+) (–) (–) (–)
27 (+) (–) n.d. (+) (–) n.d.
28 (+) (–) n.d. (–) (–) n.d.
29 (–) (–) (+) (–) (–) (+)
30 (+) (+) (+) (+) (–) (+)
31 (–) (–) (–) (–) (–) (–)
32 (+) (–) n.d. (–) (–) n.d.
33 (+) (–) n.d. (+) (–) n.d.
n.d., not done;*, positive for band at 72 kDa in Western blot analysis of MAGE-1.
Table 3. Positivity of mRNA and protein of MAGE-1 and -3
MAGE-1 MAGE-3
mRNA Immunoblot Staining mRNA Immunoblot Staining
Histology
well 5/8 4/5 1/12 2/7 4/5 1/11
mod 15/17 7/8 4/19 8/17 4/8 1/16
por 1/2 1/2 1/2 1/2 1/2 0/2
Stage
I 6/8 2/3 0/9 1/7 2/3 0/7
II 7/8 4/5 3/11 4/8 2/5 0/10
III 5/6 4/4 2/8 4/6 3/4 2/7
IVA 1/3 2/3 1/3 1/3 2/3 0/3
IVB 2/2 n.d. 0/2 1/2 n.d. 0/2
21/27 (78) 12/15 (80) 6/33 (18) 11/26 (42) 9/15 (60) 2/29 (7)
(),%; well, well differentiated hepatocellular carcinoma; mod, moderately differentiated hepatocellular carcinoma;
por, poorly differentiated hepatocellular carcinomaMAGE-1 and -3 expression in human HCC 1085
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Monoclonal antibodies 77B and 57B do not show evidence of
reciprocal cross-reactivity between MAGE-1 and -3 at the Western
level, and they recognize the specific gene products in immuno-
histochemical sections. However, the 57B mAb has recently been
suggested to cross-react with MAGE-4, -6 or -12 genes (T Boon,
personal communication) Therefore, we also performed RT-PCR
for MAGE-4, -6 and -12 and analysed the correspondence between
the expression of the genes and the protein detected by
immunoblot analysis with mAb 57B to examine whether the mAb
detected only MAGE-3 gene product. As the results, the highly
correspondent rate between the gene and the protein in MAGE-3
indicated that mAb 57B detected MAGE-3 protein rather than
MAGE-4, -6 and -12, though there was a possibility that the mAb
may detect MAGE-6 protein in a few cases.
The Western blot analysis revealed that 80 and 60% of HCCs
expressed MAGE-1 and -3 proteins respectively, though the posi-
tivities in the immunohistochemistry were lower. This discrepancy
might be caused by a lower antigenisity of the proteins in paraffin-
embedded samples. With respect to the 72-kDa protein which
cross-reacts with the mAb 77B and is frequently co-expressed
with the MAGE-1 protein in melanomas (Carrel et al, 1996; Gudat
et al, 1996). In the present study, only two of 15 HCCs expressed
this protein and these two HCCs also expressed MAGE-1 protein.
As the positive rates of MAGE-1 and -3 genes are different among
various malignancies (Weynants et al, 1994; Eura et al, 1995a,
1995b; Inoue et al, 1995; Patard et al, 1995; Russo et al, 1995;
Shichijo et al, 1995; Toh et al, 1995; Yamada et al, 1995; Corrias et
al, 1996; Mori et al, 1996; Muramoto, 1997; Sudo et al, 1997), the
expression of the 72-kDa protein might differ between melanomas
and HCCs.
Regarding the protein distribution, our results are consistent
with those of prior studies in melanomas showing that MAGE-1
and -3 gene products are immunopositive only in the malignant
portions, cytoplasmic proteins invaginating into distorted nuclei,
and distribute either homogeneously, focally or singularly
(Schultz-Thater et al, 1994; Kocker et al, 1995; Gudat et al, 1996;
Gunther et al, 1997).
An apparent discordance between the gene expression and the
protein detection of MAGE-1 and -3 has been shown in
melanomas: five expressed MAGE-1 protein whereas the gene
was detected in four samples, and seven expressed MAGE-3
protein among nine positive for the gene expression (Gudat et al,
1996; Gunther et al, 1997). This discordance was also observed in
the present study on HCCs, in which three were positive in the
Western blotting despite being negative in the gene expression.
Although the protein for the Western blot analysis might be better
preserved than the mRNA for RT-PCR, we have no explanation
for this discrepancy.
Table 4. Expression of MAGE-4, -6, -12 mRNA and immunoblot analysis
with mAb 57B
Case MAGE-3 MAGE-4 MAGE-6 MAGE-12 mAb 57B
No. mRNA mRNA mRNA mRNA immunoblot
1 (–) (–) (+) (–) (+)
7 (–) (+) (+) (–) (–)
8 (–) (–) (+) (–) (+)
10 (–) (–) (+) (–) (–)
13 (–) n.d. n.d. n.d. (–)
14 n.d. (–) (+) (–) (+)
16 (–) n.d. n.d. n.d. (–)
18 (+) (–) (+) (–) (+)
22 (+) n.d. n.d. n.d. (+)
24 (+) (–) (–) (–) (+)
25 (+) n.d. n.d. n.d. (+)
26 (–) (–) (+) (–) (–)
29 (–) (+) (+) (–) (+)
30 (+) n.d. n.d. n.d. (+)





Figure 4. MAGE-1 protein was detected in cytoplasm of HCC cells, and the
distribution pattern were homogeneous(a) or focal(b). (´200) In some
samples, the protein was recognized in the nucleus of HCC cells(c). (´400)1086 K Kariyama et al
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In the present study, we have demonstrated that MAGE-1 and
-3 proteins were detected exclusively in HCC areas regardless of
the histological grading and clinical staging. The positive rates of
MAGE-1 and -3 proteins analyzed by the immunoblotting were
higher than those examined by the immunohistochemical analysis.
Gene and protein of MAGE-1 were more frequently expressed
than those of MAGE-3 in human HCCs. Furthermore, we have
recently attempted to detect the MAGE-1 gene in small samples
gained by a 21-gauge thin-needle biopsy, and found the constitu-
tive gene expression in early HCCs (solitary and less than 20 mm
in diameter) ambiguous in histological examination. Thus, at the
present time, the detection of MAGE-1 gene by RT-PCR or gene
product by the Western blotting is the best choice for differential
diagnosis of early HCCs from non-cancerous lesions.
Collective evidence indicates that MAGE-1 and -3 peptides are
recognized by autologous cytotoxic T lymphocytes and can elicit
cytolytic activity in a MHC class I-restricted manner in vitro or in
vivo in the patients with melanoma or other malignancies (Celis
et al, 1994; van der Bruggen et al, 1994; Yamasaki et al, 1995;
Hu et al, 1996; Toso et al, 1996; Fleischhauer et al, 1997; Valomori
et al, 1997). A strong CTL response was induced in patients with
advanced melanoma by vaccination of dendritic cells pulsed with
a cocktail of peptides of tumour-associated antigens including
MAGE-1 and -3 together with or without cell lysate (Nestlé et al,
1998). The fact that not only the primary, but also metastatic,
melanomas were regressed following vaccination suggests the
clinical usefulness of the immunotherapy against tumour-associ-
ated antigen peptides. Many reports have indicated the possibility
of vaccine therapy in malignant tumours with tumour-rejection
antigen peptides; however, most of them did not show the protein
expression in tumours. We clarified in the present study that the
gene products of MAGE-1 and -3 were frequently expressed in
HCCs and thus the possibility of immunotherapy against MAGE-1
or -3 epitopes in HCC patients could be envisaged moreover.
In conclusion, we demonstrated the expression of MAGE-1 and
-3 genes and gene products in human HCCs. Our findings indicate
that the detection of the genes and gene products of MAGE-1 and
-3 is a useful tool for differential diagnosis between early HCCs
and non-cancerous lesions, and immunotherapy targeting the
peptides derived from MAGE-1 and -3 proteins appears to be
feasible in patients with HCC.
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